C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 1.955 USD -3.46% Market Closed
Market Cap: 37.9m USD

Wall Street
Price Targets

0HS8 Price Targets Summary
Caladrius Biosciences Inc

Wall Street analysts forecast 0HS8 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0HS8 is 12.233 USD with a low forecast of 8.386 USD and a high forecast of 14.53 USD.

Lowest
Price Target
8.386 USD
329% Upside
Average
Price Target
12.233 USD
526% Upside
Highest
Price Target
14.53 USD
643% Upside
Caladrius Biosciences Inc Competitors:
Price Targets
ASMB
Assembly Biosciences Inc
9% Upside
KMDA
Kamada Ltd
121% Upside
6855
Ascentage Pharma Group International
78% Upside
2696
Shanghai Henlius Biotech Inc
56% Upside
ELDN
Eledon Pharmaceuticals Inc
423% Upside
NIOX
Niox Group PLC
21% Upside
688235
Beigene Ltd
33% Upside
VYGR
Voyager Therapeutics Inc
257% Upside

Revenue
Forecast

Revenue Estimate
Caladrius Biosciences Inc

For the last 13 years the compound annual growth rate for Caladrius Biosciences Inc's revenue is -16%. The projected CAGR for the next 3 years is 117%.

-16%
Past Growth
117%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Caladrius Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Caladrius Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 0HS8's stock price target?
Price Target
12.233 USD

According to Wall Street analysts, the average 1-year price target for 0HS8 is 12.233 USD with a low forecast of 8.386 USD and a high forecast of 14.53 USD.

What is Caladrius Biosciences Inc's Revenue forecast?
Projected CAGR
117%

For the last 13 years the compound annual growth rate for Caladrius Biosciences Inc's revenue is -16%. The projected CAGR for the next 3 years is 117%.

Back to Top